Sanofi SNY
We take great care to ensure that the data presented and summarized in this overview for Sanofi is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SNY
View all-
Dodge & Cox San Francisco, CA76.3MShares$3.69 Billion2.67% of portfolio
-
Morgan Stanley New York, NY17.8MShares$860 Million0.08% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa13.4MShares$646 Million0.32% of portfolio
-
Invesco Ltd. Atlanta, GA11.7MShares$564 Million0.13% of portfolio
-
Bank Of America Corp Charlotte, NC11.6MShares$560 Million0.06% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$489 Million0.01% of portfolio
-
Barrow Hanley Mewhinney & Strauss LLC Dallas, TX7.84MShares$379 Million1.56% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.75MShares$278 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.65MShares$225 Million0.05% of portfolio
-
Goldman Sachs Group Inc New York, NY3.65MShares$177 Million0.03% of portfolio
Latest Institutional Activity in SNY
Top Purchases
Top Sells
About SNY
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Transactions at SNY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|